ACS Chemical Neuroscience
June 10, 2025
Santosh Kumar Prajapati, Shreyasi Majumdar, Snehapriya Murari et al.
14 citations
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition triggered by exposure to traumatic events, with complex neurobiological anomalies that remain incompletely understood. This review aims to comprehensively explore the neurocircuitry, neurochemical dysregulation, and emerging pharmacological targets associated with PTSD, offering a consolidated framework for developing...
Current Medicinal Chemistry
June 2, 2025
Jinlong Zhang, Xingxing Dang, Jiang Lin et al.
The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a...
Psychopharmacology
June 1, 2025
Carmen Abate, Richard Young, Małgorzata Dukat et al.
2 citations
Rationale α-ET (α-ethyltryptamine), a homolog of the classical hallucinogen α-methyltryptamine, was once prescribed clinically as an antidepressant. Classical psychedelic drugs are currently of interest as potential pharmacotherapy for psychiatric disorders. Objectives Drug discrimination was used to (a) determine if α-ET-like stimulus effects could be engendered by the prototypical...
Progress in neuro-psychopharmacology & biological psychiatry
April 2, 2025
Viktoriia Kurkova, Olga Winkler, Andrew J. Greenshaw et al.
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...
Social Work
April 1, 2025
Maha N. Mian, Jordan Horan, Taweh Hunter et al.
1 citation
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two...
CNS Drugs
April 1, 2025
Balwinder Singh
6 citations
Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recover, a subset develop post-traumatic stress disorder (PTSD), a debilitating condition characterized by distressing memories, avoidance behaviors, hyperarousal, and mood disturbances. The National Comorbidity Survey reports a lifetime PTSD prevalence...
The Australian and New Zealand journal of psychiatry
April 1, 2025
Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani et al.
16 citations
To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder. Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted...
Contemporary clinical trials communications
February 1, 2025
Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum
5 citations
This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...
CNS Spectrums
January 30, 2025
Steve O'Brien, David Nutt
5 citations
This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds...
PLoS One
2025
Filip Stanicic, Vladimir Zah, Dimitrije Grbic et al.
5 citations
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severity post-traumatic stress disorder (PTSD). To provide a comprehensive summary of investigational MDMA-AT and current treatments for PTSD. A search was conducted in PubMed and Embase (December 20, 2023). Populations included adults with chronic,...